Tech Company Financing Transactions
Selva Therapeutics Funding Round
Private investors participated in a $3 million Series A capital raise for Selva Therapeutics. This venture round was announced on 7/22/2020.
Transaction Overview
Company Name
Announced On
7/22/2020
Transaction Type
Venture Equity
Amount
$3,000,000
Round
Series A
Investors
private investors (Kenneth Kelley)
Proceeds Purpose
The proceeds of the financing will be used to rapidly advance SLV213 into clinical trials as a leading oral drug candidate for the treatment of COVID-19, the disease caused by SARS-CoV-2 infection.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
San Diego, CA 22434
USA
San Diego, CA 22434
USA
Phone
Undisclosed
Website
Email Address
Overview
Selva Therapeutics is a privately held biotechnology company dedicated to the development of therapeutics for infectious diseases. The company's lead drug candidate, SLV213, is a novel small molecule antiviral therapy with activity against a broad range of viruses that threaten global health, including SARS-CoV-2, the coronavirus that causes COVID-19.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ted Daley
Chief Scientific Officer
Felix Frueh
Browse more venture capital transactions:
Prev: 7/22/2020: Readout Health venture capital transaction
Next: 7/22/2020: Mission Control venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs